Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19.

MLA

Santos, Arnoldo, et al. “Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19.” Journal of the American College of Cardiology, vol. 79, no. 1, Jan. 2022, pp. e13–14. EBSCOhost, https://doi.org/10.1016/j.jacc.2021.10.030.

APA

Santos, A., Martínez-Milla, J., Pérez-Calvo, C., & Ibáñez, B. (2022). Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19. Journal of the American College of Cardiology, 79(1), e13–e14. https://doi.org/10.1016/j.jacc.2021.10.030

Chicago

Santos, Arnoldo, Juan Martínez-Milla, César Pérez-Calvo, and Borja Ibáñez. 2022. “Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19.” Journal of the American College of Cardiology 79 (1): e13–14. doi:10.1016/j.jacc.2021.10.030.